intramuscular bpc 157 bpc-157 injection technique subcutaneous or Oral vs Injectable BPC-157: Differences, Benefits, and When to Use Eac – Revolution Health & Wellness Peptide Step-by-step with Dr. Rodenberg: How – bpc-157 subcutaneous vs intramuscular injection

IGF-1 LR3 binds the alpha subunit of the IGF-1 receptor tyrosine kinase, inducing autophosphorylation of the beta subunit on specific tyrosine residues (Y1131, Y1135, Y1136) that create docking sites for insulin receptor substrate (IRS) proteins and Shc adaptor proteins

After this, its sterility cannot be guaranteed

The peptide vial research guide covers proper handling in more detail if you want additional context on best practices

Phase 2 Side-Effect Frequencies at 4.5 mg/week (Lancet 2021) Side Effect Nausea Incidence at 4.5 mg/week 47% Side Effect Injection-site reactions Incidence at 4.5 mg/week 43% Side Effect Constipation Incidence at 4.5 mg/week 21% Side Effect Fatigue Incidence at 4.5 mg/week 20% Side Effect Allergic reactions (any) Incidence at 4.5 mg/week 10% Side Effect Vomiting Incidence at 4.5 mg/week 8% Side Effect Loose stools Incidence at 4.5 mg/week 7% Side Effect Headache Incidence at 4.5 mg/week 7% Side Effect Indigestion Incidence at 4.5 mg/week 4% Incidence was lower at lower doses